Neuland Laboratories Ltd share price declined by 1.64% to Rs 19288.35 after the company's net profit tumbled by 30.56% to Rs 147.67 crore, while revenue from operations reduced 17.35% to Rs 641.58 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.82 lakh crore, easing 5.74%. It has improved by 0.41% over last one week and advanced by 11.45% in last one month while the market capitalization of Neuland Laboratories Ltd has slipped by 2.17% and 11.49% in the same period respectively. Profit before tax (PBT) of Neuland Laboratories Ltd stood at Rs 197.85 crore in Q2 FY26, rallying 1026.07% year-on-year, and nosediving by 31.18% quarter-on-quarter. EBITDA came in at Rs 214 crore, surging by 705.11% YoY and tanking 27.29% sequentially. Total expenses softened by 9.87% to Rs 445.25 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 228.77 crore, slightly declining by 0.88% YoY, while employee benefits expense was at Rs 106.43 crore, expanding by 8.08% YoY. For the TTM ended FY26, revenue from operations surged 36.98% to Rs 2022.99 crore, while net profit saw a strong growth of 39.94% to Rs 364.0 crore, compared to previous TTM. EBITDA jumped by 32794% to Rs 544.33 crore, and PBT witnessed a strong rise of 41.19% to Rs 488.98 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 346.68 crore in FY26, as against Rs 317.4 crore in FY25. Neuland Laboratories Ltd soared by 47.54% in last one year, significantly outperforming the benchmark BSE Sensex which has softened by 3.20% during the same period.
